NCT05828446Recruiting
Improving Hepatocellular Carcinoma Screening
Prospective Comparison of Diagnostic Performance and Cost-effectiveness of US and Abbreviated MRI for Hepatocellular Carcinoma Screening
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI. Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- First submitted
- 19 Jan 2023
- Start date
- 1 Apr 2023
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Naik Vietti Violi
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05828446
What you commit to
- Study type: Interventional
- Planned participants: 330
- From 1 Apr 2023 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior liver nodule categorized as LI-RAD 4, 5 or M
Other illness
- History of HCC
- History of other malignancy
- History of liver transplantation
- Any other condition making the patient unsuitable for the study
- Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study
Other
- Pregnancy
- MRI or MRI contrast agent precaution
Who the study is looking for
- All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations.
- Informed Consent signed by the subject
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lausanne University Hospital Coordinator of this site? Confirm its status | Lausanne | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.